SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: Ed Ajootian who wrote (2136)3/26/1999 8:49:00 AM
From: sam  Read Replies (1) | Respond to of 10280
 
Briefing.com's take:
Sepracor Inc. (SEPR) 118 1/4: specialty pharmaceutical company receives FDA approval to market Xopenex inhalation solution for the treatment of and prevention of bronchospasm; Xopenex demonstrated excellent safety and efficacy, and a duration of action that lasted up to 8 hours in clinical trials; see press release.....

Maybe its just me, but I can't imagine why it would "sell off" on this news, considering it has "sold off" in anticipation of a potential snag.